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Abstract
Background: Paracoccidioidomycosis (PCM) is systemic mycosis caused by the thermal dimorphic fungus of genus
Paracoccidioides, leading to either acute/subacute (AF) or chronic (CF) clinical forms. Numerous CF patients after
treatment exhibit sequels, such as pulmonary and adrenal fibrosis. Monocytes are cells that are involved in the
inflammatory response during active infection as well as in the fibrogenesis. These cells comprise a heterogeneous
population with distinct phenotypic and functional activities. The scope of this study was to identify changes
regarding functional and phenotypical aspects in monocytes comparing CF PCM patients on antifungal treatment
versus non-treated patients (PMC-p).
Methods: Twenty-three CF PCM composed of 11 non-treated patients (NTG) and 12 patients in apparent cure
(ACG) were studied. Sixteen healthy individuals were used as control group (CG). Monocyte subsets were
determined by immunophenotyping based on CD14 and CD16 expression. Cellular function was measured
in vitro with and without stimulation with lipopolysaccharide (LPS) and P. brasiliensis exoantigen (PbAg) for
24 hours. Independent samples were compared using unpaired t tests, dependent samples were analyzed by
paired t-test. Groups of more than two independent samples were analyzed using an ANOVA, with Tukey’s
post-test. Significance was set up at p <0.05.
Results: Our results showed high counts of peripheral blood CD14+CD16+ and CD14+CD16++ monocytes in
untreated PCM-p accompanied by intense production of pro-inflammatory cytokines (IL-1β and TNF-α) and
profibrotic growth factors (TGF-β1 and bFGF) by monocytes challenged with P. brasiliensis antigens. After the
introduction of antifungal therapy, the counts of CD14+CD16+ cells returned to baseline while CD14+CD16++
counts remained high. Interestingly, counts of CD14+CD16++ monocytes remained elevated even 52 ± 7 months
after successful antifungal treatment. Furthermore, the ACG-patients showed preserved pro-inflammatory
activity in the presence of specific antigen stimuli and high spontaneous production of TNF-α by monocytes.
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Conclusions: Infection with Paracoccidioides leads to initiation of a specific proinflammatory response by
monocytes of PCM-p during active disease and in the apparent cure. A profibrotic profile by monocytes was
observed only at admission. Furthermore, PCM-p with apparent cure showed high spontaneous production of
TNF-α and high counts of CD14+CD16++ monocytes, probably induced by hypoxia duo to fibrotic sequelae.
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Background
Paracoccidioidomycosis (PCM) is a systemic and granu-
lomatous mycosis caused by thermally dimorphic fungi
of the Paracoccidioides brasiliensis complex and P. lutzii
[1-3] and is characterized by antigen-dependent im-
munosuppression [4]. The active disease presents two
main clinical forms: the acute/subacute form (AF) and
the chronic form (CF). PCM patients (PCM-p) with the
AF are typically young and normally show a short duration
of the symptomatology (median of two months), exhibiting
clinical manifestations that involve organs rich in the
mononuclear phagocytic system (e.g. bone marrow, liver,
spleen). CF usually affects adult males who present a long
duration of the symptomatology (>6 months) and exhibit
predominant pulmonary and mucocutaneous involvement
[5]. After treatment, numerous CF patients present seque-
lae, especially pulmonary fibrosis and emphysema, and
Addison’s syndrome [6].
As observed in other diseases caused by intracellular
pathogens, the control of PCM depends on an effective
and protective Paracoccidioides-specific host cellular
immune response [7]. Although the adaptive immune
response toward PCM is better characterized, immunity
against the genus Paracoccidioides is complex and
involves other immune cell subsets, including mono-
nuclear phagocytes [7]. The immunophenotyping and
functions under inflammatory and steady-state condi-
tions of murine and human monocyte subsets have
been investigated [8], and several studies have shown
that monocyte subsets play different roles in the innate
immune response during infectious processes and
fibrogenesis [9,10].
In humans, monocyte subsets can be identified by the
expression of the surface molecules CD14 and CD16 [11].
CD14+CD16− monocytes are termed classical monocytes
and represent approximately 90-95% of human mono-
cytes. These cells express high amounts of CCR1 and
CCR2 and are characterized by moderate levels of the
fractalkine receptor CX3CR1 and low HLA-DR. Further-
more, these cells exhibit intense phagocytic activity, pro-
duce high amounts of IL-10 upon lipopolysaccharide
(LPS) stimulation and are the main precursors of tissue
macrophages (reviewed in Zimmermann et al. [12]).
Intermediate (CD14+CD16+) and non-classical or inflam-
matory (CD14+CD16++) subsets produce large amounts of
proinflammatory mediators and are up-regulated in many
inflammatory disorders, such as rheumatoid arthritis, ath-
erosclerosis, bacterial sepsis and various hepatic diseases.
Intermediate monocytes display high levels of HLA-DR,
the mannose receptor and CCR5, and inflammatory
monocytes exhibit high expression of CX3CR1 [12].
In PCM, the recovery of the immune response is a
crucial step for considering successful the antifungal
therapy. However, few reports have addressed immuno-
logical studies during the follow-up of PCM-p. Because
interference with monocyte subset distribution and acti-
vation may be involved in PCM, we evaluated the
phenotypic and functional aspects of the monocytes in




Twenty-three CF PCM patients (PCM-p) from the Trop-
ical Diseases Ward and Outpatient Clinic for Paracocci-
dioidomycosis at the University Hospital, Faculdade de
Medicina de Botucatu (FMB), UNESP–Univ. Estadual
Paulista, Botucatu, SP, Brazil, were studied. Cases with
clinical manifestations that were compatible with PCM
were considered either confirmed or probable [13].
Cases were considered confirmed when the typical Para-
coccidioides genus yeast forms were identified in the
clinical specimens and probable when only serum-
specific antibodies were detected using a double agar gel
immunodiffusion test (DID). All patients exhibited pul-
monary involvement and were classified as having clin-
ical CF. Patients who exhibited neoplasia, inflammation,
infectious diseases or pregnancy were not enrolled.
Ethics statement
This study was approved by the Research Ethics Com-
mittee of FMB-UNESP (#3145/2009). Written informed
consent to participate and to publish the data was ob-
tained from all participants. In this study IRB was signed
by all the adult patients. We had no IRB signed by the
closest relative or the legal representative.
Experimental design
PCM-p were categorized into two groups: the non-
treated group (NTG), consisting of 11 newly diagnosed
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patients, and the apparent cure group (ACG), consisting
of 12 PCM-p who did not show any signs or symptoms
and had a normal erythrocyte sedimentation rate (ESR),
negative serology, and at least 2 full years of non-
treatment after complete antifungal therapy [6]. The
homogeneity of the groups was determined based on
sex, age (years), clinical form and degree of severity, spe-
cific antibody serum levels and information on antifun-
gal treatment (Table 1). Sixteen age- and sex-matched
healthy individuals were selected among blood donors
from the same geographical area to form the CG.
Determination of the peripheral blood monocyte subsets
Venous blood was collected in Vacutainer tubes (BD,
Becton Dickinson, Franklin Lakes, NJ, USA) containing
EDTA anticoagulant. Whole blood (100 μl) was added into
polystyrene tubes containing the following monoclonal
antibodies: phycoerythrin (PE)-conjugated mouse IgG1
anti-human CD14, clone HCD14; peridinin chlorophyll
protein complex (PerCP)-conjugated mouse IgG1 anti-
human CD16, clone 3G8; and allophycocyanin (APC)-con-
jugated mouse IgG1 anti-human CD45, clone HI30, all of
which were purchased from BioLegend (San Diego, CA,
USA). The tubes were incubated for 20 min at 4°C and
again after FACS lysing solution was added. The cells were
washed with BD Pharmingen™ stain buffer and analyzed
using a FACSCalibur (BD). The data were analyzed
using the FlowJo software (Tree Star Inc, USA). The cell
counts were calculated based on peripheral leucocyte
count (WBC).
Monocyte culture
Twenty milliliters of venous blood were collected in
Vacutainer® tubes (BD) containing heparin anticoagulant.
Mononuclear cells were separated using a Ficoll-
Hypaque (Sigma, St Louis, MO, USA) density gradient
and suspended in 1.0 ml of RPMI-1640 medium con-
taining L-glutamine and 25 mM HEPES buffer (Gibco,
Table 1 Clinical characterization of the patients




P1 M 60 Moderate 16 NTG - - -
P2 M 53 Severe 128 NTG - - -
P3 M 59 Moderate 32 NTG - - -
P4 F 47 Moderate 64 NTG - - -
P5 M 44 Moderate 64 NTG - - -
P6 M 51 Mild NR NTG - - -
P7 M 64 Moderate 32 NTG - - -
P8 M 59 Moderate 32 NTG - - -
P9 M 52 Moderate 8 NTG - - -
P10 M 47 Moderate 32 NTG - - -
P11 M 37 Moderate 4 NTG - - -
P12 M 56 Moderate 16 ACG CMX 25 28
P13 M 39 Severe 64 ACG CMX 173 37
P14 M 60 Mild 16 ACG CMX 97 45
P15 M 56 Moderate 16 ACG CMX 26 3
P16 M 50 Moderate 512 ACG CMX 53 62
P17 M 42 Moderate 8 ACG CMX 28 83
P18 M 42 Moderate NR ACG ITC 31 69
P19 M 39 Moderate 2 ACG ITC 32 27
P20 M 40 Severe 128 ACG CMX/ITC 33(CMX)/49(ITC) 89
P21 M 42 Severe 64 ACG CMX/ITC 6(CMX)/131(ITC) 53
P22 M 51 Severe 128 ACG CMX/ITC 44(CMX)/12(ITC) 60
P23 M 53 Severe 64 ACG CMX 84 65
DID = double agar gel immunodiffusion test; NR = non-reagent; NTG = non-treated group; ACG = apparent cure group; CMX = cotrimoxazole; ITC = Itraconazole.
*Homogeneity (NTG x ACG):
Age: NTG =52 (37–64); ACG = 46 (39–60); p =0.18 (Mann–Whitney U test).
Degree of severity: NTG = ACG; p =0.31 (Fisher’s exact test).
DID admission: NTG =32 (NR-1:128); ACG =32 (NR-1:512); p =0.66 (Mann–Whitney U test).
**Length of treatment (Mean ± SEM): 68 ± 14; Length after treatment (Mean ± SEM): 52 ± 7.
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Grand Island, NY, USA) supplemented with 10% fetal
calf serum (Gibco), penicillin (100 UI/ml) and strepto-
mycin (100 μg/ml) (Gibco). The cell concentration was
adjusted to 2.0 × 106 mononuclear phagocytes ml−1, as
judged by the uptake of 0.02% neutral red. The mono-
nuclear cells were placed in 96-well, flat-bottomed micro-
titer plates (Costar, Cambridge, MA, USA) and incubated
for 2 hours at 37°C and 5% CO2 in a humidified chamber
to allow the monocytes to adhere and spread. Non-
adherent cells were removed by washing the wells 3 times
with RPMI-1640 medium, and the remaining adherent
cells (>90% mononuclear phagocytes as assessed by the
CD14 cell-surface expression) were used for experiments.
The adherent monocytes were cultured at 37°C and
5% CO2 in supplemented RPMI-1640 in the presence
of medium only or optimal concentrations of LPS
(10 μg ml−1, Sigma) and P. brasiliensis exoantigen
(20 μg ml−1, Pb113 strain). After 24 hours, the cell-free
supernatants were harvested and stored at −80°C pending
cytokine analysis.
Quantification of cytokines
The cytokines TGF-β1, CCL3/MIP-1α, VEGF and bFGF
were quantified using ELISA with the Cytokine Duo-Set
Kit (R&D Systems, Minneapolis, USA). IL-1β, IL-6, IL-
10, TNF-α and IL-12p70 were quantified using flow
cytometry and the Human Inflammation Kit, BD™, Cyto-
metric Bead Array (BD).
Statistical analysis
Statistical tests were performed using the GraphPad
v.5.00 software (GraphPad Software Inc, San Diego, CA,
USA), and significance was set up at p ≤0.05 for all of
the analyses. The homogeneity of the groups NTG and
ACG was determined by Mann–Whitney U test and
Fisher’s exact test. Comparisons of two independent
samples were performed using unpaired t test, two
dependent samples using t-paired test, and comparison
of more than two independent samples were performed
using an ANOVA, with Tukey’s post-test [14].
Results
Distribution of the blood peripheral monocyte subsets of
PCM-p before antifungal treatment, during the antifungal
treatment and after apparent cure
Although in both groups of PCM-p the total monocyte
count (CD45+CD14+) was in the normal clinical range
compared to healthy controls, the NTG group still
showed significantly elevated CD45+CD14+ cell counts
(Figure 1C). In this group, we also observed high
counts of CD14+CD16+ and CD14+CD16++ (Figure 1A,
B and C). Five PCM-p from NTG were also evaluated
after the introduction of antifungal therapy; we
observed a significant decrease in CD45+CD14+ cells
and the counts of CD14+CD16++ cells remained high
(Table 2). PCM-p from ACG showed high counts of
CD14+CD16++ (Figure 1C).
Production of inflammatory mediators/cytokines by
monocytes from PCM-p before treatment and after
apparent cure
We determined the concentrations of IL-1β, IL-6, TNF-
α, IL-10, IL-12p70, CCL3/MIP-1α, TGF-β1, FGF-b and
VEGF in the supernatants of monocyte cell cultures in
the presence or absence of LPS-nonspecific and P. brasi-
liensis antigen-specific stimuli. Among the mediators an-
alyzed in the cell-free supernatant, VEGF and IL-12p70
had levels that were below the detection limits.
Independent of the stimuli, no differences in the pro-
duction of IL-6, IL-10 and MIP-1α were observed among
the groups (Figure 2). The production of IL-1β and TNF-
α after specific-antigen challenge was higher in PCM-p re-
gardless of treatment compared with the CG. Moreover,
the spontaneous production of TNF-α was higher in both
groups of patients than in the CG (Figure 2).
The specific-stimulus production of TGF-β1 was
higher in non-treated patients than normal subjects
and similar to PCM-p with apparent cure (Figure 2).
Similarly, the specific and non-specific stimulus pro-
duction of bFGF was higher in non-treated patients
than normal subjects and similar to PCM-p with ap-
parent cure (Figure 2).
Discussion
Some aspects should be considered regarding the im-
munological evaluations of CF PCM-p. First, the CF is
usually caused by reactivation of latent foci that were
maintained for an unknown amount of time, potentially
as long as 30 years [15]; thus, the host has previously or-
ganized an adaptive immune response against the genus
Paracoccidioides that was efficacious for some time.
Indeed, the prevalence of healthy subjects from endemic
areas who have a positive intradermal skin test to
paracoccidioidin and negative test for histoplasmin can
reach 50% [16,17]. Second, due to the long duration
of symptomatology of >6 months, the clinical and im-
munological evaluations performed at admission occur
in PCM-p who have responded to the paracoccidioidal
antigens but without success because they show progres-
sion of the signs and symptoms [5]. In addition, the in-
flammatory response is intense but inefficacious [18-21].
Third, the lungs are the entry route for the fungus and
one of the main target organs in the CF [22]. In this
organ, peri-bronchial pulmonary lesions of the epithelioid
granulomatous type are observed, followed by confluence
and nodule formation, occasionally with central necrosis,
which can drain its contents and form cavities [23,24].
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Furthermore, intense collagen I and III (reticulin fibers)
deposition around the granuloma that interconnects
neighboring structures, such as bronchi and blood
vessels, occurs. In addition, reticulin proliferation is
observed in the alveolar septae in non-granulomatous
areas [25]. It is important to highlight that upon ad-
mission, CF patients typically present all of these pul-
monary alterations, as identified by several biopsies
and necroscopic studies [24,26].
Here, we showed for the first time high counts of per-
ipheral blood CD14+CD16+ intermediate as well as
CD14+CD16++ non-classic monocytes in untreated
PCM-p. Studies on infectious processes, such as Gram-
negative bacteremia, have shown an increased number
of monocytes CD16+ that normalizes after efficacious
treatment [27]. In the present study, we observed
that after the introduction of the antifungal therapy,
the count of total monocytes and CD14+CD16+ cells
Figure 1 Distribution of peripheral blood monocyte subsets. A. Dot plots showing the gate strategies used to identify the monocyte subsets
(from CD45+CD14+) of healthy individuals and untreated patients. B. Distribution of the total peripheral blood monocytes and their subsets in
healthy individuals (CG, n =16), patients with PCM (PCM-p) before antifungal treatment (NTG, n =9) and PCM-p with apparent cure (ACG, n =12).
Values are expressed as the mean ± standard deviation (cell counts of total peripheral leukocytes - CD45+ cells) and comparisons were performed
by ANOVA with Tukey’s post-test. Different letters indicate significant differences among the groups (p ≤0.05).
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decreased. All groups of PCM-p exhibited high counts
of CD14+CD16++.
In addition to infectious processes, a recent report
showed a higher frequency of intrahepatic intermediate
monocytes in patients with chronic inflammatory and fi-
brotic liver diseases [28]. According to the authors, the
intermediate subset can modulate liver fibrogenesis. Al-
though we did not separately evaluate the functions of
the monocyte subsets, the high percentage of CD16+
monocytes in untreated CF PCM-p could be related to
two typical morpho-functional aspects of these patients:
an intense inflammatory response and pro-fibrotic activ-
ity. We observed high production of pro-inflammatory
cytokines (IL1-β and TNF-α) and pro-fibrotic growth
factors (TGF-β1 and bFGF). This profile was similar to
that observed in previous studies that evaluated several
pro-inflammatory cytokines and TGF-β1 [18,21]. Con-
sidering that TGF-β1 is a pleiotropic cytokine that ex-
hibits a central role in fibrogenesis [29], as well as
potent anti-inflammatory/regulatory activity [30], the
bFGF dosage enhances early fibrogenesis in CF PCM-p.
In addition, we observed that some patients showed a
normal distribution of monocyte subsets and/or levels of
TGF-β1 and bFGF. This finding could be associated with
clinical observations of different degrees of fibrosis upon
patient admission. Our group recently developed an al-
gorithmic method to quantify pulmonary fibrosis and
emphysema [31], and a study to correlate the different
degrees of fibrosis and with the immune response is
ongoing.
Herein, we also demonstrate for the first time that P.
brasiliensis antigens significantly enhance the production
of IL1-β, TNF-α, TGF-β1 and bFGF by peripheral blood
monocytes of PCM-p, suggesting that fungal metabolites
play an important role in the activation of these cells.
Considering that monocytes are precursors for various
tissue macrophages and dendritic cells and secrete sev-
eral immune mediators in the pulmonary milieu during
inflammation, it is possible that the recruitment of
specific-stimulated monocytes into paracoccidioidal le-
sions could contribute to deleterious inflammatory tissue
damage and trigger fibroblast and fibrocyte activation
[32]. This hypothesis is supported by several studies that
have demonstrated an array of strategies used by P.
brasiliensis or its metabolites to manipulate host cells to
survive and propagate (reviewed in Mendes-Giannini
et al. [33]). Thus, we believe that our findings should
open new perspectives for investigation, especially re-
lated to fibrosis in PCM-p.
We also investigated for the first time the functional
aspects of the peripheral blood monocytes of PCM-p
after treatment, i.e., with apparent cure. We found
high levels of TNF-α and IL-1β in antigen-stimulated
cell culture supernatants, which suggests preserved
pro-inflammatory activity of the PCM-p monocytes
when stimulated by paracoccidioidal antigens. In
addition, we observed higher counts of CD16++ mono-
cytes and high levels of spontaneous TNF-α release by
monocytes from these patients. Considering that the
pulmonary sequelae observed in CF PCM-p typically
become worse after antifungal therapy is initiated
[6,34], it is possible that the higher levels of TNF-α
are due to hypoxemia [35].
Conclusions
In summary, the present study showed that untreated
PCM-p exhibit intense production of pro-inflammatory
and pro-fibrotic mediators by monocytes challenged
with P. brasiliensis antigens. They also exhibit high
counts of CD14+CD16+ and CD14+CD16++ monocytes.
After the introduction of antifungal therapy, the counts
of CD14+CD16+ returned to baseline. After complete
treatment, monocytes from PCM-p showed preserved
pro-inflammatory activity against specific stimuli, high
spontaneous production of TNF-α and high counts of
CD14+CD16++. Although the role of these cells is com-
plex, we suggest that during the active disease, these
Table 2 Distribution of monocyte subsets of PCM-p during the follow-up
ID patient Before Treatment During the treatment
CD45+CD14+ CD14+CD16− CD14+CD16+ CD14+CD16++ CD45+CD14+ CD14+CD16− CD14+CD16+ CD14+CD16++ Length of
treatment
(months)
P3 348 327 16 5 331 307 6 18 17 (ITC)
P6 933 716 158 58 221 430 16 18 20 (CMX)
P7 1164 959 118 88 776 610 4 23 20 (ITC)
P8 457 346 82 30 214 290 6 10 20 (CMX)




















Different letters indicate significant differences between the groups (p ≤0.05, t-paired test; A >B).
Values expressed as cell counts/μl.
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Figure 2 Determination of IL-1β, IL-6, TNF-α, MIP-1α, IL-10, TGF-β1 and FGFb levels in the cell-free supernatant obtained from monocytes
from healthy subjects (CG, n =6), PCM-p before treatment (NTG, n =7) and PCM-p with apparent cure (ACG, n =8). The cells were cultured
in the absence (spontaneous production – unstimulated) or presence of lipopolysaccharide - LPS and P. brasiliensis antigen – AgPb
(stimulated production). Values are expressed as the mean ± standard deviation and comparisons were performed by ANOVA with Tukey’s
post-test. Different letters indicate significant differences among the groups (p ≤0.05).
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cells could act both in the proinflammatory response as
wells as in the fribrogenesis; and after the treatment, the
findings seems to be a consequence of hypoxemia due
to pulmonary fibrosis.
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